EMEA recommends Orphan Drug Designation for AX200 in the treatment of Spinal Cord Injury
SYGNIS Pharma AG announced that it has received a positive recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) for AX200 in the treatment of spinal cord injury.
A spinal cord injury (SCI) is damage or trauma to the spinal cord which interrupts communication of the brain with body regions below the site of injury. Spinal cord injuries are predominantly caused by accidents and, in the majority of cases, result in life-long loss of control of motor functions and sensation. After the primary injury to the spinal cord, a cascade of events leads to progressive loss of tissue which may further deteriorate the patient’s prognosis.
Pre-clinical studies have shown that AX200 can counteract the processes leading to neuronal cell death. In addition, the compound has demonstrated a profound ability to foster neuronal regeneration and to support neuronal plasticity which facilitates functional recovery after SCI.
In April 2008, SYGNIS received Orphan Drug Designation from the European Commission for AX200 in the treatment of Amyotrophic Lateral Sclerosis.
Other news from the department research and development
